Botulinum Toxin in the Treatment of Headache

Botulinum toxin in the management of temporomandibular disorders: a systematic review

(2020) S. Thambar et al.   BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY

A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine

(2020) Paul K. Winner et al.   HEADACHE

Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice

(2020) Olivia Begasse de Dhaem et al.   HEADACHE

Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

(2020) Lanfranco Pellesi et al.   HEADACHE

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

(2020) Rami Burstein et al.   HEADACHE

Access to Migraine Treatments in Ontario, Canada: A Review of the Ontario Drug Benefit Program

(2020) Susan Cape   HEADACHE

Efficacy of Botulinum Toxin in Tension-Type Headaches: A Systematic Review of the Literature

(2019) Brin Freund et al.   Pain Practice

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

(2019) William B. Young et al.   JOURNAL OF HEADACHE AND PAIN

A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism

(2019) Jalpesh Patel et al.   BRITISH DENTAL JOURNAL

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

(2019) Messoud Ashina et al.   CEPHALALGIA

Prognosis Following Discontinuation of OnabotulinumA Therapy in “Super‐responding” Chronic Migraine Patients

(2019) Jason Ching et al.   HEADACHE

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

(2019) John F. Rothrock et al.   HEADACHE

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Migraine is first cause of disability in under 50s: will health politicians now take notice?

(2018) Timothy J. Steiner et al.   JOURNAL OF HEADACHE AND PAIN

CGRP as the target of new migraine therapies — successful translation from bench to clinic

(2018) Lars Edvinsson et al.   Nature Reviews Neurology

Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine

(2018) Ioana Ion et al.   Toxins

The Expanding Therapeutic Utility of Botulinum Neurotoxins

(2018) Elena Fonfria et al.   Toxins

Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity

(2018) Elena Fonfria et al.   Toxins

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation

(2018) Lars Bendtsen et al.   JOURNAL OF HEADACHE AND PAIN

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes

(2017) Andrew M. Blumenfeld et al.   HEADACHE

Fremanezumab - a humanized monoclonal anti-CGRP antibody — inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors

(2017) Agustin Melo-Carrillo et al.   JOURNAL OF NEUROSCIENCE

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Evidencia y experiencia del uso de onabotulinumtoxinA en neuralgia del trigémino y cefaleas primarias distintas de la migraña crónica

(2017) S. Santos-Lasaosa et al.   NEUROLOGIA

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS

Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?

(2016) XiChun Zhang et al.   CEPHALALGIA

Interventional Treatment for Post-traumatic Headache

(2016) Francis X. Conidi   Current Pain and Headache Reports

Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache

(2016) David M. Simpson et al.   NEUROLOGY

A Research Synthesis of Therapeutic Interventions for Whiplash-Associated Disorder (WAD): Part 5 – Surgical and Injection-Based Interventions for Chronic WAD

(2016) Robert W Teasell et al.   Pain Research & Management

Botulinum toxin drugs: brief history and outlook

(2015) D. Dressler   JOURNAL OF NEURAL TRANSMISSION

Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents

(2015) Roshni Ramachandran et al.   NEUROBIOLOGY OF DISEASE

OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine

(2015) Eva Cernuda-Morollón et al.   PAIN

Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing

(2015) Sabine Pellett et al.   Toxins

Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?

(2014) Eva Cernuda-Morollón et al.   CEPHALALGIA

Innervation of Rat and Human Dura Mater and Pericranial Tissues in the Parieto-Temporal Region by Meningeal Afferents

(2014) Markus Schueler et al.   HEADACHE

Headache Direction and Aura Predict Migraine Responsiveness to Rimabotulinumtoxin B

(2012) Patrick M. Grogan et al.   HEADACHE

Onabotulinum toxin A treatment of cervicogenic headache: A randomised, double-blind, placebo-controlled crossover study

(2011) Mattias Linde et al.   CEPHALALGIA

Activation of central trigeminovascular neurons by cortical spreading depression

(2010) XiChun Zhang et al.   ANNALS OF NEUROLOGY

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

(2010) SK Aurora et al.   CEPHALALGIA

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

(2010) HC Diener et al.   CEPHALALGIA

On muscle spindles, dystonia and botulinum toxin

(2010) R. L. Rosales et al.   EUROPEAN JOURNAL OF NEUROLOGY

Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program

(2010) Andrew Blumenfeld et al.   HEADACHE

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

(2010) David W. Dodick et al.   HEADACHE

A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study

(2009) Ninan T. Mathew et al.   HEADACHE